Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study (Q34317204)

1 August 2017

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study (English)

1 reference

1 August 2017

0 references

1 reference

1 reference

1 reference

Nezam Afdhal

4

0 references

Patrick Marcellin

1

object named as

Patrick Marcellin

1 reference

1 August 2017

3

Maria Buti

1 reference

1 August 2017

Edward Gane

2

1 reference

1 August 2017

William Sievert

5

1 reference

1 August 2017

Ira M Jacobson

6

1 reference

1 August 2017

Mary Kay Washington

7

1 reference

1 August 2017

George Germanidis

8

1 reference

1 August 2017

John F Flaherty

9

1 reference

1 August 2017

Raul Aguilar Schall

10

1 reference

1 August 2017

Jeffrey D Bornstein

11

1 reference

1 August 2017

Kathryn M Kitrinos

12

1 reference

1 August 2017

G Mani Subramanian

13

1 reference

1 August 2017

John G McHutchison

14

1 reference

1 August 2017

E Jenny Heathcote

15

1 reference

1 August 2017

language of work or name

English

0 references

publication date

10 December 2012

1 reference

1 August 2017

1 reference

1 August 2017

381

1 reference

1 August 2017

468-475

1 reference

1 August 2017

9865

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Risk and predictors of mortality associated with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

1 reference

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Diagnosis and quantitation of fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Sampling variability of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

An appraisal of the histopathological assessment of liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Ethnicity and body mass index are associated with hepatitis C presentation and progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961425-1

7 January 2021

10.1016/S0140-6736(12)61425-1

Identifiers

DOI

1 reference

1 August 2017

1 reference